
|Articles|July 1, 2001
- Pharmaceutical Executive-07-01-2001
- Volume 0
- Issue 0
Generic Threat
Author(s)Kevin Gopal
Epsom, Surrey, United Kingdom—Pharmaceutical companies struggle to be taken seriously when they talk of facing pressures. A quick look at the bottom line often suggests they are overstating their worries. But new evidence shows they are being squeezed by generic competition and falling R&D output.
Advertisement
Articles in this issue
about 25 years ago
Pharmacies: OTC Price Warsabout 25 years ago
One Disease at a Timeabout 25 years ago
Overview of the Industry: A World of Opportunitiesabout 25 years ago
The Power Shiftabout 25 years ago
A Giant Stumblesabout 25 years ago
Overruled: No More Dual Pricingabout 25 years ago
SubmergedAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
How Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?
2
Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory
3
Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia
4
Staying Ahead of Viral Evolution: Q&A with Robert Allen, Ph.D
5




